Download PDF
Nervenheilkunde 2022; 41(07/08): 497-501
DOI: 10.1055/a-1772-0284
Übersichtsarbeit

Steigerung der Therapietreue durch niederschwellige Kontakte

Warum die Rolle der Nurse in der MS-Therapie nicht unterschätzt werden sollteIncreasing adherence to therapy through low-threshold contactsWhy the role of the nurse in MS therapy should not be underestimated
Michael Lang
1   NeuroPoint Patientenakademie Ulm
,
Lukas Cepek
1   NeuroPoint Patientenakademie Ulm
2   Nervenfachärztliche Gemeinschaftspraxis Ulm
,
Daniela Rau
1   NeuroPoint Patientenakademie Ulm
2   Nervenfachärztliche Gemeinschaftspraxis Ulm
,
Nadine Denkinger
1   NeuroPoint Patientenakademie Ulm
2   Nervenfachärztliche Gemeinschaftspraxis Ulm
,
Katja Behrens
1   NeuroPoint Patientenakademie Ulm
2   Nervenfachärztliche Gemeinschaftspraxis Ulm
,
Anselm Kornhuber
1   NeuroPoint Patientenakademie Ulm
2   Nervenfachärztliche Gemeinschaftspraxis Ulm
› Author Affiliations
› Further Information
    Permissions and Reprints

ZUSAMMENFASSUNG

Besonders bei Menschen mit chronischen Erkrankungen, z. B. Multiple Sklerose (MS), stellt die Einhaltung der verordneten Therapie über einen langen Zeitraum eine große Herausforderung dar. Teils alarmierend niedrige Adhärenzraten und ein dadurch geringerer Therapienutzen sind die Folge. Neben einem verbesserten Nebenwirkungsmanagement haben sich Vertrauen in die Therapie und wahrgenommenes Engagement des Arztes als modifizierbare positive Einflussgrößen auf die Adhärenz herausgestellt. Die nötige umfassende Betreuung der Patienten über Jahre hinweg kann dabei nicht allein durch den Arzt bewältigt werden, sondern bedarf idealerweise der Unterstützung durch Patientenprogramme und speziell ausgebildeter MS-Schwestern (Nurses), die dem Patienten eine unkomplizierte Kontaktaufnahme zur Besprechung von Sorgen oder Fragen unabhängig von Arztterminen ermöglicht. Diese niederschwelligen Kontakte konnten als signifikanter Faktor identifiziert werden, der über die Therapietreue entscheiden kann. Zusätzlich haben in den letzten Jahren digitale Anwendungen wie Apps bei langen und unvorhersehbaren Krankheitsverläufen wie bei der MS an Bedeutung gewonnen und können ohne Belastung des ärztlichen Zeitbudgets als smarte Therapiebegleiter fungieren.

ABSTRACT

Adhering to the prescribed therapy over a long period of time displays a major challenge, for people with chronic diseases such as multiple sclerosis (MS). This often results in alarmingly low adherence rates and lower therapeutic benefit. In addition to improved management of side effects, confidence in the treatment and perceived engagement of the physician have turned out to be modifiable factors positively influencing adherence. The necessary comprehensive care of the patients over the years cannot be managed by the physician alone, but ideally requires the support of patient support programs and specially trained nurses. The availability of nurses enables the patient to easily contact them to discuss concerns or questions independently of doctor’s appointments. These so-called low-threshold contacts could be identified as a significant factor that can determine adherence. In recent years digital applications have gained importance for long and unpredictable disease courses such as MS and can act as smart therapy companions without burdening the physician’s time budget.

Schlüsselwörter

Adhärenz - Multiple Sklerose - E-Health - Krankheitsmanagement - Patientenengagement

Key words

Adherence - multiple sclerosis - e-health - disease management - patient engagement


Publication History

Article published online:
28 July 2022

© 2022. Thieme. All rights reserved.

© Georg Thieme Verlag KG Stuttgart · New York
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 WHO. Adherence to long-term therapies: evidence for action www.who.int/chp/knowledge/publications/adherence_introduction.pdf
  • 2 Menzin J, Caon C, Nichols C. et al Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm 2013; 19: S24-40
    CrossrefPubMedGoogle Scholar
  • 3 Washington F, Langdon D.. Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review. J Neurol. 2021 DOI: 10.1007/s00415-021–10850-w
    CrossrefPubMedGoogle Scholar
  • 4 Treadaway K, Cutter G, Salter A. et al Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009; 256: 568-576
    CrossrefPubMedGoogle Scholar
  • 5 Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence 2010; 04: 1-9
    CrossrefPubMedGoogle Scholar
  • 6 Seehausen M, Hänel P. Arzt-Patienten-Kommunikation: Adhärenz im Praxisalltag effektiv fördern. Dtsch Arztebl 2011; 108: A-2276/B-1918
    Google Scholar
  • 7 Online Ä.. Budgetbegrenzung sorgt für weniger Arzttermine am Quartalsende. https://www.aerzteblatt.de/nachrichten/87482/Budgetbegrenzung-sorgt-fuer-weniger-Arzttermine-am-Quartalsende
    Google Scholar
  • 8 Rae-Grant A, Day GS, Marrie RA. et al Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018; 90: 789-800
    CrossrefPubMedGoogle Scholar
  • 9 Gerber B, Cowling T, Chen G. et al The impact of treatment adherence on clinical and economic outcomes in multiple sclerosis: Real world evidence from Alberta, Canada. Mult Scler Relat Disord 2017; 18: 218-224
    CrossrefPubMedGoogle Scholar
  • 10 Lugaresi A, Rottoli MR, Patti F. Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. Expert Rev Neurother 2014; 14: 1029-1042
    CrossrefPubMedGoogle Scholar
  • 11 Remington G, Rodriguez Y, Logan D. et al Facilitating medication adherence in patients with multiple sclerosis. Int J MS Care 2013; 15: 36-45
    CrossrefPubMedGoogle Scholar
  • 12 Steinberg SC, Faris RJ, Chang CF. et al Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig 2010; 30: 89-100
    CrossrefPubMedGoogle Scholar
  • 13 Devonshire V, Lapierre Y, Macdonell R. et al The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011; 18: 69-77
    CrossrefPubMedGoogle Scholar
  • 14 Flachenecker P, Kobelt G, Berg J. et al New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany. Mult Scler 2017; 23: 78-90
    CrossrefPubMedGoogle Scholar
  • 15 Osterloh F. Arzneimittelreport: Zu viele Psychopharmaka. Dtsch Arztebl Int 2012; 109: A-1408
    Google Scholar
  • 16 vdek. Daten zum Gesundheitswesen: Arzneimittel www.vdek.com/presse/daten/d_ausgaben_arzneimittel.html
  • 17 Frohman E, Phillips T, Kokel K. et al Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist 2002; 08: 227-236
    CrossrefPubMedGoogle Scholar
  • 18 Mohr DC, Goodkin DE, Likosky W. et al Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Mult Scler 1996; 02: 222-226
    CrossrefPubMedGoogle Scholar
  • 19 Genné M.. Betrachtung der Adhärenz von Patienten mit Multipler Sklerose unter immunmodulatorischer Therapie und deren Einflussgrößen in einem ambulanten Multiple Sklerose Zentrum: Medizinische Fakultät der Universität Ulm. 2010
    PubMedGoogle Scholar
  • 20 Multiple-Sklerose-Therapie. Sprint und Marathon zugleich. Pharmazeutische Zeitung 2014; 44
  • 21 DMSG. MS-Schwester/MS-Therapiemanagement: DMSG Fachfortbildung für ‚MS-Schwestern‘ www.dmsg.de/service/fachfortbildungen/ms-schwester
  • 22 Filipi ML, Beavin J, Brillante RT. et al Nurses’ perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis. Int J MS Care 2014; 16: 55-60
    CrossrefPubMedGoogle Scholar
  • 23 Kukowski B, Rehberg-Weber K, Taipale K. et al Subcutaneous Interferon Beta Therapy in Multiple Sclerosis Patients – Characterization of Injection Site Reactions and Flu-Like Symptoms in a Daily Practice Setting – Results from the Non-Interventional Study PERFECT. Patient Prefer Adherence 2021; 15: 1091-1100
    CrossrefPubMedGoogle Scholar
  • 24 Mohr DC, Goodkin DE, Masuoka L. et al Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis. Mult Scler 1999; 05: 192-197
    CrossrefPubMedGoogle Scholar
  • 25 Hayward-Könnecke H. Fortbildung Multiple Sklerose und Kinderwunsch. Psychiatrie und Neurologie 2017: 2
    PubMedGoogle Scholar
  • 26 NeuroPoint Patientenakademie www.neuropoint.de
  • 27 Stockl KM, Shin JS, Gong S. et al Improving patient self-management of multiple sclerosis through a disease therapy management program. Am J Manag Care 2010; 16: 139-144
    PubMedGoogle Scholar
  • 28 Lenz F, Harms L. The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study. Adv Ther 2020; 37: 2999-3009
    CrossrefPubMedGoogle Scholar
  • 29 Tan H, Yu J, Tabby D. et al Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study. Mult Scler 2010; 16: 956-963
    CrossrefPubMedGoogle Scholar
  • 30 Roche J, McCarry Y, Mellors K. Enhanced patient support services improve patient persistence with multiple sclerosis treatment. Patient Prefer Adherence 2014; 08: 805-811
    CrossrefPubMedGoogle Scholar
  • 31 Organization WH. mHealth. New horizons for health through mobile technologies https://apps.who.int/iris/handle/10665/44607
  • 32 Marziniak M, Brichetto G, Feys P. et al The Use of Digital and Remote Communication Technologies as a Tool for Multiple Sclerosis Management: Narrative Review. JMIR Rehabil Assist Technol 2018; 05: e5
    CrossrefPubMedGoogle Scholar
  • 33 Lavorgna L, Brigo F, Moccia M. et al e-Health and multiple sclerosis: An update. Mult Scler 2018; 24: 1657-1664
    CrossrefPubMedGoogle Scholar
  • 34 Kern R, Haase R, Eisele JC. et al Designing an Electronic Patient Management System for Multiple Sclerosis: Building a Next Generation Multiple Sclerosis Documentation System. Interact J Med Res 2016; 05: e2
    CrossrefPubMedGoogle Scholar
  • 35 Akter S, Ray P.. mHealth – an Ultimate Platform to Serve the Unserved. Yearb Med Inform. 2010: 94-100
    PubMedGoogle Scholar
  • 36 Tachakra S, Wang XH, Istepanian RS. et al Mobile e-health: the unwired evolution of telemedicine. Telemed J E Health 2003; 09: 247-257
    CrossrefPubMedGoogle Scholar
  • 37 Haase R, Wunderlich M, Dillenseger A. et al Improving multiple sclerosis management and collecting safety information in the real world: the MSDS3D software approach. Expert opinion on drug safety 2018; 17: 369-378
    CrossrefPubMedGoogle Scholar
  • 38 Matthews PM, Block VJ, Leocani L. E-health and multiple sclerosis. Curr Opin Neurol 2020; 33: 271-276
    CrossrefPubMedGoogle Scholar
  • 39 Giovannoni G, Butzkueven H, Dhib-Jalbut S. et al Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord 2016; 09 (Suppl. 01) S5-S48
    CrossrefPubMedGoogle Scholar
  • 40 D’Amico E, Haase R, Ziemssen T. Review: Patient-reported outcomes in multiple sclerosis care. Mult Scler Relat Disord 2019; 33: 61-66
    CrossrefPubMedGoogle Scholar
  • 41 Brichetto G, Zaratin P. Measuring outcomes that matter most to people with multiple sclerosis: the role of patient-reported outcomes. Curr Opin Neurol 2020; 33: 295-299
    CrossrefPubMedGoogle Scholar
  • 42 Lang M, Rau D, Cepek L. et al An ID-Associated Application to Facilitate Patient-Tailored Management of Multiple Sclerosis. Brain Sci 2021: 11
    PubMedGoogle Scholar
  • 43 Feys P, Giovannoni G, Dijsselbloem N. et al The importance of a multi-disciplinary perspective and patient activation programmes in MS management. Mult Scler 2016; 22: 34-46
    CrossrefPubMedGoogle Scholar
  • 44 Gallien P, Gich J, Sanchez-Dalmau BF. et al Multidisciplinary management of multiple sclerosis symptoms. Eur Neurol 2014; 72 (Suppl. 01) 20-25
    CrossrefPubMedGoogle Scholar
  • 45 Denis L, Namey M, Costello K. et al Long-term treatment optimization in individuals with multiple sclerosis using disease-modifying therapies: a nursing approach. J Neurosci Nurs 2004; 36: 10-22
    CrossrefPubMedGoogle Scholar
  • 46 Bundesministerium für Gesundheit. www.bundesgesundheitsministerium.de/digital-healthcare-act.html Accessed 25 May 2021
    Google Scholar
  • 47 BfArM. DiGa-Verzeichnis https://diga.bfarm.de/de/verzeichnis